Neurocrine Biosciences (NBIX) Projected to Post Quarterly Earnings on Thursday

Neurocrine Biosciences (NASDAQ:NBIX) is projected to post its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect Neurocrine Biosciences to post earnings of $1.66 per share and revenue of $890.8760 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:30 PM ET.

Neurocrine Biosciences Price Performance

Shares of Neurocrine Biosciences stock opened at $182.83 on Wednesday. The firm has a 50 day simple moving average of $166.48 and a 200 day simple moving average of $145.59. Neurocrine Biosciences has a fifty-two week low of $122.14 and a fifty-two week high of $182.91. The firm has a market cap of $18.38 billion, a P/E ratio of 28.17, a P/E/G ratio of 0.74 and a beta of 0.39.

Wall Street Analysts Forecast Growth

NBIX has been the topic of a number of recent research reports. Wall Street Zen upgraded Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, April 25th. Wells Fargo & Company boosted their target price on Neurocrine Biosciences from $175.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. Citigroup upped their price target on Neurocrine Biosciences from $242.00 to $246.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Sanford C. Bernstein assumed coverage on Neurocrine Biosciences in a report on Friday, May 22nd. They issued an “outperform” rating and a $221.00 price target on the stock. Finally, Guggenheim lifted their price objective on Neurocrine Biosciences from $175.00 to $200.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $194.05.

Insider Transactions at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director Kevin Charles Gorman sold 245,088 shares of Neurocrine Biosciences stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $154.33, for a total transaction of $37,824,431.04. Following the completion of the sale, the director owned 511,293 shares of the company’s stock, valued at approximately $78,907,848.69. The trade was a 32.40% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard F. Pops sold 15,000 shares of Neurocrine Biosciences stock in a transaction on Friday, May 15th. The stock was sold at an average price of $157.65, for a total transaction of $2,364,750.00. Following the sale, the director directly owned 34,480 shares of the company’s stock, valued at $5,435,772. This represents a 30.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 394,172 shares of company stock valued at $62,221,181. 4.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Neurocrine Biosciences

Institutional investors have recently made changes to their positions in the stock. Geneos Wealth Management Inc. lifted its stake in Neurocrine Biosciences by 143.6% in the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after buying an additional 135 shares during the period. Meeder Asset Management Inc. grew its position in shares of Neurocrine Biosciences by 651.6% during the 4th quarter. Meeder Asset Management Inc. now owns 233 shares of the company’s stock worth $33,000 after buying an additional 202 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in shares of Neurocrine Biosciences during the 4th quarter worth about $39,000. Kestra Advisory Services LLC bought a new stake in shares of Neurocrine Biosciences in the 4th quarter valued at about $53,000. Finally, Aster Capital Management DIFC Ltd increased its stake in shares of Neurocrine Biosciences by 74.4% in the 4th quarter. Aster Capital Management DIFC Ltd now owns 614 shares of the company’s stock valued at $87,000 after acquiring an additional 262 shares during the last quarter. 92.59% of the stock is owned by institutional investors and hedge funds.

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research?driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.